Targeting angiogenesis in advanced cervical cancer.

Abstract

Patients with advanced stage or recurrent cervical cancer represent a population with limited chemotherapeutic options. More specifically, patients with recurrent disease have a poor salvage rate, with a 5-year survival rate of less than 10%. This year, the first prospective phase III clinical trial exploring the anti-angiogenic agent, bevacizumab, was published, meeting its primary endpoint, with a significant improvement in overall survival. As such, a review of anti-angiogenic therapy in the treatment of this disease is warranted.

DOI: 10.1177/1758834014543794

Cite this paper

@article{Eskander2014TargetingAI, title={Targeting angiogenesis in advanced cervical cancer.}, author={Ramez N. Eskander and Krishnansu Sujata Tewari}, journal={Therapeutic advances in medical oncology}, year={2014}, volume={6 6}, pages={280-92} }